AstraZeneca and insitro announced a drug-discovery and licensing collaboration aimed at metabolic dysfunction–associated steatohepatitis (MASH) and cardiomyopathies. AstraZeneca will pay insitro $40 million upfront and could provide up to $1.46 billion in development and commercial milestones as the teams use insitro’s Virtual Human platform to identify biological drivers and advance selected programs.